AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Ankle Brachial IndexAnklePeripheral Vascular DiseasesPeripheral Arterial DiseaseAnkle JointAnkle InjuriesIntermittent ClaudicationBrachial ArteryLegArterial Occlusive DiseasesTibial ArteriesLower ExtremityIschemiaWalkingBlood Pressure DeterminationLateral Ligament, AnklePopliteal ArteryPredictive Value of TestsRisk FactorsBlood PressureFemoral ArteryVascular PatencyUltrasonography, Doppler, DuplexUltrasonography, DopplerSprains and StrainsDiabetic AngiopathiesCross-Sectional StudiesFollow-Up StudiesProspective StudiesExercise TestAtherosclerosisAngioplasty, BalloonTreatment OutcomeCardiovascular DiseasesTime FactorsRegional Blood FlowC-Reactive ProteinPhotoplethysmographyPrevalenceChi-Square DistributionCohort StudiesRisk AssessmentTalusSeverity of Illness IndexBody Mass IndexFootJoint InstabilityArthrodesisRange of Motion, ArticularOrthotic DevicesLigaments, ArticularBracesBiomechanical PhenomenaFibulaSubtalar JointFoot InjuriesGaitTarsus, AnimalRetrospective StudiesAthletic InjuriesProprioceptionAnkle FracturesTarsal BonesElectromyographyTorque

Resting energy expenditure in subjects with and without intermittent claudication. (25/396)

 (+info)

Relation of plasma midregional proatrial natriuretic peptide to target organ damage in adults with systemic hypertension. (26/396)

 (+info)

Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. (27/396)

 (+info)

Lower extremity artery stenosis distribution in an unselected elderly population and its relation to a reduced ankle-brachial index. (28/396)

 (+info)

Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index. (29/396)

Cardio-ankle vascular index (CAVI) has been established as a marker of arterial stiffness, which is increased in hypertensive patients. CAVI reflects the stiffness of the aorta, femoral artery, and tibial artery. Sunitinib, multi-targeted tyrosine kinase inhibitor with both anti-angiogenic and anti-tumor activities, has been proved effective in patients with gastrointestinal stromal tumors. However, the treatment with sunitinib is often complicated by side effects such as hypertension. We describe an 84-year-old woman with gastrointestinal stromal tumor, who showed changes in arterial stiffness preceding the appearance of hypertension in the early phase after sunitinib initiation. The patient received sunitinib (50 mg given daily) for gastrointestinal stromal tumor. We assessed the influence of sunitinib on arterial stiffness every 7 days by measuring CAVI. The CAVI, which reflects arterial stiffness, was increased from 9.95 at baseline to 11.65 at 7 days after the initiation of sunitinib, whereas the blood pressure remained unchanged (117/72 and 119/76 mmHg). At 14 days after sunitinib initiation, the blood pressure was increased to 159/89 mmHg, indicating the occurrence of hypertension, while the CAVI was 11.90, the similar level detected at 7 days. Subsequently, sunitinib treatment was discontinued, because of the marked decrease in blood platelets. Both blood pressure and CAVI, together with blood platelets, were restored to the baseline values at 12 days after cessation of sunitinib. In conclusion, the increase in the CAVI preceded the appearance of sunitinib-induced hypertension. Arterial stiffness assessed by CAVI may be useful for early detection of sunitinib-induced hypertension.  (+info)

Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002. (30/396)

 (+info)

Eccentric strength and endurance in patients with unilateral intermittent claudication. (31/396)

 (+info)

Ankle brachial index measurement in primary care: are we doing it right? (32/396)

 (+info)